Pulmonary Arterial Hypertension PAH Clinical Trials

18 recruitingLast updated: June 18, 2026

There are 18 actively recruiting pulmonary arterial hypertension pah clinical trials across 16 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4. Top locations include São Paulo, São Paulo, Brazil, Riga, Latvia, Aurora, Colorado, United States. Updated daily from ClinicalTrials.gov.


Pulmonary Arterial Hypertension PAH Trials at a Glance

18 actively recruiting trials for pulmonary arterial hypertension pah are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in São Paulo, Riga, and Aurora. Lead sponsors running pulmonary arterial hypertension pah studies include University of Sao Paulo General Hospital, Assistance Publique - Hôpitaux de Paris, and Amsterdam UMC, location VUmc.

Browse pulmonary arterial hypertension pah trials by phase

Treatments under study

About Pulmonary Arterial Hypertension PAH Clinical Trials

Looking for clinical trials for Pulmonary Arterial Hypertension PAH? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Arterial Hypertension PAH trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Arterial Hypertension PAH clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1

Study of Intravenous ZMA001 in Healthy Subjects

Pulmonary Arterial Hypertension PAH
National Heart, Lung, and Blood Institute (NHLBI)96 enrolled1 locationNCT05967299
Recruiting
Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Pulmonary Arterial Hypertension PAHPulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.40 enrolled19 locationsNCT07175038
Recruiting
Phase 2

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension PAH
Regeneron Pharmaceuticals99 enrolled6 locationsNCT07318597
Recruiting
Phase 1Phase 2

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.120 enrolled32 locationsNCT07593027
Recruiting
Phase 3

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

ComorbiditiesCardiovascular Disease (CVD)Pulmonary Arterial Hypertension PAH
Assistance Publique - Hôpitaux de Paris186 enrolled1 locationNCT07245680
Recruiting
Phase 1

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension PAH
Joseph C. Wu15 enrolled1 locationNCT06872112
Recruiting
Not Applicable

Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension

Pulmonary HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
University of Sao Paulo General Hospital215 enrolled1 locationNCT07120789
Recruiting
Not Applicable

AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?

Pulmonary Arterial Hypertension PAH
University of Sao Paulo General Hospital72 enrolled1 locationNCT07457762
Recruiting

The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension

Pulmonary Arterial HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
University of Sao Paulo General Hospital121 enrolled1 locationNCT07013149
Recruiting

PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch

Pulmonary Arterial HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
University of Sao Paulo General Hospital139 enrolled1 locationNCT06998329
Recruiting
Phase 4

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

Pulmonary Arterial HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension WHO Group I
Amsterdam UMC, location VUmc20 enrolled1 locationNCT06658522
Recruiting
Not Applicable

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension PAH
University of Rochester55 enrolled1 locationNCT06477640
Recruiting

COMPERA / COMPERA-KIDS

Pulmonary Arterial Hypertension PAHPulmonary Hypertension (PH)
Technische Universität Dresden14,000 enrolled7 locationsNCT01347216
Recruiting
Not Applicable

Comparison of Sequential to Initial Combination Therapy in PAH

Pulmonary Arterial Hypertension PAH
Second Affiliated Hospital, School of Medicine, Zhejiang University376 enrolled1 locationNCT06968962
Recruiting
Not Applicable

imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce

Pulmonary Arterial HypertensionPulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
University of Sao Paulo General Hospital61 enrolled1 locationNCT06850792
Recruiting
Phase 3

PAH Exercise Study

Exercise TherapyPulmonary Arterial Hypertension PAH
University of Washington10 enrolled1 locationNCT06941441
Recruiting

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

Pulmonary Arterial Hypertension PAHLung Fibrosis Interstitial
Fondazione IRCCS Policlinico San Matteo di Pavia16 enrolled1 locationNCT06917196
Recruiting

Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis

Systemic Sclerosis (SSc)Pulmonary Arterial Hypertension PAHHome Monitoring Follow-up
Oslo University Hospital20 enrolled1 locationNCT06865118